Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients.

Lorenzo BertaniLaura BagliettoLuca AntonioliMatteo FornaiGherardo TapeteEleonora AlbanoLinda CeccarelliMaria Gloria MumoloCarolina PellegriniErsilia LucenteforteNicola de BortoliMassimo BelliniSantino MarchiCorrado BlandizziFrancesco Costa

Published in: British journal of clinical pharmacology (2020)

In UC patients, the serum patterns of IL-6 and IL-8 at baseline and over the first 6 weeks of treatment with VDZ could be useful to predict therapeutic outcome.

Keyphrases

end stage renal disease
ulcerative colitis
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
type diabetes
metabolic syndrome
adipose tissue
ultrasound guided
skeletal muscle
insulin resistance